An in-depth exploration of the evolving understanding of inflammation in COPD, focusing on the differences between type 1/3 and type 2 inflammatory pathways and their clinical relevance. Experts will discuss current gaps in COPD management and the potential of precision medicine to improve outcomes for patients with persistent symptoms or frequent exacerbations. The program will also review recent clinical trial data on type 2 biologics, strategies for identifying appropriate candidates through biomarkers and comorbidities, and key areas for future research, including long-term outcomes, treatment tapering, and therapy optimization.* Produced by the AII Assembly Host:• Sara Assaf, MD - Assistant Professor, Division of Pulmonary, Critical Care and Sleep at the University of New MexicoGuests• Nick Hanania, MD, MS - Director, Airways Clinical Research Center, Brown Foundation, Professor of Medicine, Baylor College of Medicine • Stephanie Christenson, MD MAS - Associate Professor, Division of Pulmonary, Critical Care, Allergy, & Sleep, UCSF• Surya P Bhatt MD, MSPH - Professor of Medicine, Endowed Professor of Airways Disease, University of Alabama at Birmingham• Klaus Rabe, MD, PhD, FERS - Professor of Pulmonary Medicine, University of Kiel🔹 00:00:00 | Introduction (0–4 min)🔹 00:04:04 | Setting the Stage: Why Type 2 Inflammation Matters in COPD🔹 00:08:07 | The Science Behind COPD and Type 2 Pathways🔹 00:12:08 | How Inflammation Shapes Disease Progression🔹 00:16:11 | Current and Emerging Treatments for COPD🔹 00:24:20 | Biomarkers and Precision Medicine🔹 00:32:25 | New Frontiers and Ongoing Research🔹 00:52:41 | Wrapping Up and Key Takeaways

Ver todos los episodios